Inovio Biomedical Corporation Partner Tripep Provides Update on its Hepatitis C DNA Vaccine Program

SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corp. (AMEX:INO), focused on the development of DNA-based vaccines for cancers and infectious diseases and a novel alternative to surgery to treat localized cancers, announced today that its partner, Tripep AB of Sweden, has provided an update regarding its application to the Swedish Medical Products Agency (MPA) to initiate a Phase I clinical trial for its proprietary DNA vaccine, ChronVac-C®, administered using Inovio’s MedPulser® DNA Delivery System. Tripep announced it intends to file with the MPA a modified application designed to permit clinical testing of ChronVac-C® in subjects already infected with hepatitis C virus instead of healthy volunteers, as per the original application. Tripep intends to initiate the phase I/II clinical study at the Center for Gastroenterology at Karolinska University Hospital in Sweden beginning in late 2007.